Early-stage biotech decisions that help drive success
49:12
Early-stage biotech companies often face pressure to move quickly from discovery toward clinical development. But decisions made early in a program can have downstream consequences for CMC development, manufacturability, process scale-up, regulatory readiness, and commercialization. In this expert panel discussion, leaders from Thermo Fisher Scientific and biotech organizations share real-world perspectives on the decisions that can shape development strategy and long-term program success. Key topics discussed include: ✓ Why CMC strategy should be considered early in biotech development ✓ Assessing manufacturability and developability risks during discovery ✓Building a target product profile (TPP) early ✓Designing processes and unit operations with scale-up in mind ✓Balancing development speed, quality, and risk ✓Understanding when to build capabilities in-house versus working with external partners ✓ Preparing for effective technology transfer to CDMOs ✓The role of manufacturing, quality, and supply considerations in investor confidence ✓ How platform strategies can support development without replacing molecule-specific CMC planning ✓ How AI, machine learning, and data modeling can support process development and experimental design ✓ Why high-quality, structured data is foundational for effective AI applications ✓ Building CMC capabilities that support programs from discovery through manufacturing The panel emphasizes an important principle for emerging biotech companies: manufacturing and CMC should not be treated as problems to solve later. Early, stage-appropriate planning can help identify and address risks before they become more difficult and expensive to resolve
